SEARCH

SEARCH BY CITATION

References

  • Briggs A. (2000) Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 17:479500.
  • Briggs A, Sculpher M, Claxton K. (2006) Decision modelling for health economic evaluation. Oxford University Press, New York, USA.
  • Brooks R. (1996) EuroQol: the current state of play. Health Policy 37:5372.
  • Bureau of Trade and Economic Indices. (2011) Report for consumer price index of THAILAND YEAR 2011 BASE YEAR 2007. Ministry of Commerce, Nonthaburi, Thailand.
  • Campbell MK, Torgerson DJ. (1999) Bootstrapping: estimating confidence intervals for cost-effectiveness ratios. QJM 92:177182.
  • Center of Essential Information for All Health Officers. (2011) Reference price database. Ministry of Public Health, Nonthaburi, Thailand.
  • Chantarangsu S, Mushiroda T, Mahasirimongkol S, Kiertiburanakul S, Sungkanuparph S, Manosuthi W, Tantisiriwat W, Charoenyingwattana A, Sura T, Chantratita W, Nakamura Y. (2009) HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients. Pharmacogenet Genomics 19:139146.
  • Chantratita W, Chantarangsu S, Kiertiburanakul S, Sungkanuparph S, Charoenyingwattana A, Mahasirimongkol S. (2011) Integrating HIV-1 pharmacogenomics into the universal coverage health care system in thailand: from scientific evidence to policy. J Pharmacogenomics Pharmacoproteomics S6:001. doi:10.4172/2153-0645.S6-001.
  • Chen P, Lin J-J, Lu C-S, Ong C-T, Hsieh PF, Yang C-C, Tai C-T, Wu S-L, Lu C-H, Hsu Y-C, Yu H-Y, Ro L-S, Lu C-T, Chu C-C, Tsai J-J, Su Y-H, Lan S-H, Sung S-F, Lin S-Y, Chuang H-P, Huang L-C, Chen Y-J, Tsai P-J, Liao H-T, Lin Y-H, Chen C-H, Chung W-H, Hung S-I, Wu J-Y, Chang C-F, Chen L, Chen Y-T, Shen C-Y. (2011) Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med 364:11261133.
  • Chung W-H, Hung S-I, Hong H-S, Hsih M-S, Yang L-C, Ho H-C, Wu J-Y, Chen Y-T. (2004) Medical genetics: a marker for Stevens–Johnson syndrome. Nature 428:486.
  • Dong D, Sung C, Finkelstein EA. (2012) Cost-effectiveness of HLA-B*1502 genotyping in adult patients with newly diagnosed epilepsy in Singapore. Neurology 79:12591267.
  • Grunkemeier GL, Wu Y. (2004) Bootstrap resampling methods: something for nothing? Ann Thorac Surg 77:11421144.
  • Harr T, French L. (2010) Toxic epidermal necrolysis and Stevens–Johnson syndrome. Orphanet J Rare Dis 5:39.
  • Health Product Vigilance Center. (2011a) Genetic: SJS/TEN in Thais. HPVC Safety News, Thai Food and Drug Administration, Ministry of Public Health, Nonthaburi, Thailand.
  • Health Product Vigilance Center. (2011b) Report of adverse drug reaction 2006–2011. In Health Product Vigilance Center, Thai Food and Drug Administration (Eds). Health Product Vigilance Center, Nonthaburi, Thailand.
  • Hu Y, Huang Y, Quan F, Lu Y, Wang XF. (2011) Comparison of the retention rates between carbamazepine and valproate as an initial monotherapy in Chinese patients with partial seizures: a ten-year follow-up, observational study. Seizure 20:208213.
  • Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP, Lin YL, Lan JL, Yang LC, Hong HS, Chen MJ, Lai PC, Wu MS, Chu CY, Wang KH, Chen CH, Fann CS, Wu JY, Chen YT. (2005) HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA 102:41344139.
  • Kankeawlar P, Phurmsuwan A. (2006) Costs of adverse drug reactions of inpatients at female medical ward. Published online: 9 September 2011.
  • Kupatawintu P, Pheancharoen S, Srisuddee A, Tanaka H, Tadokoro K, Nathalang O. (2010) HLA-A, -B, -DR haplotype frequencies in the Thai Stem Cell Donor Registry. Tissue Antigens 75:730736.
  • Lim K, Kwan P, Tan C. (2008) Association of HLA-B*1502 allele and carbamazepine induced severe adverse cutaneous drug reaction among Asians, a review. Neurol Asia 13:1521.
  • Locharernkul C, Loplumlert J, Limotai C, Korkij W, Desudchit T, Tongkobpetch S, Kangwanshiratada O, Hirankarn N, Suphapeetiporn K, Shotelersuk V. (2008) Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population. Epilepsia 49:20872091.
  • McCormack M, Alfirevic A, Bourgeois S, Farrell J, Kasperaviciute D, Carrington M, Sills G, Marson T, Jia X, de Bakker P, Chinthapalli K, Molokhia M, Johnson M, O'Connor G, Chaila E, Alhusaini S, Shianna K, Radtke R, Heinzen E, Walley N, Pandolfo M, Pichler W, Park BK, Depondt C, Sisodiya S, Goldstein D, Deloukas P, Delanty N, Cavalleri G, Pirmohamed M. (2011) HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med 364:11341143.
  • Moore RA, Wiffen PJ, Derry S, McQuay HJ. (2011) Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev 2011(3):CD007938.
  • National Drug Commitee. (2008) National list of essential medicines 2008. The National Health Security Office, Nonthaburi, Thailand.
  • Permsuwan U, Guntawongwan K, Buddhawongsa P. (2008) Handling time in economic evaluation studies. J Med Assoc Thai 91(Suppl. 2):S53S58.
  • Rattanavipapong W, Koopitakkajorn T, Praditsitthikorn N, Teeraw-attananon Y. (2011) The consultation meeting on the research project “Economic evaluation of HLA-B*1502 genotyping in carbamazepine induced Stevens–Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN)” on 5 August 2011. Health Intervention and Technology Assessment Program, Nonthaburi, Thailand.
  • Rattanavipapong W, Koopitakkajorn T, Praditsitthikorn N, Teerawa-ttananon Y, Mahasirimongkol S. (2012a) The consultation meeting on the research project “Economic evaluation of HLA-B*1502 genotyping in carbamazepine induced Stevens–Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN)” on 31 January 2012. Health Intervention and Technology Assessment Program, Nonthaburi, Thailand.
  • Rattanavipapong W, Koopitakkajorn T, Praditsitthikorn N, Teeraw-attananon Y, Mahasirimongkol S. (2012b) Economic evaluation of HLA-B*1502 genotyping in carbamazepine induced Stevens–Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). Health Intervention and Technology Assessment Program, Nonthaburi, Thailand.
  • Riewpaiboon A. (2008) Measurement of costs. J Med Assoc Thai 91(Suppl. 2):S28S37.
  • Riewpaiboon A. (2011) Standard cost lists for health technology assessment. Health Technology Assessment Program, Ministry of Public Health, Nonthaburi, Thailand.
  • Romphruk A, Romphruk A, Kongmaroeng C, Klumkrathok K, Paupairoj C, Leelayuwat C. (2010) HLA class I and II alleles and haplotypes in ethnic Northeast Thais. Tissue Antigens 75:701711.
  • Sharma P, Kim K. (2012) A comparison of PLS and ML bootstrapping techniques in SEM: a monte carlo study. The 7th International Conference on Partial Least Squares and Related Methods, Houston, TX.
  • Tassaneeyakul W, Tiamkao S, Jantararoungtong T, Chen P, Lin SY, Chen WH, Konyoung P, Khunarkornsiri U, Auvichayapat N, Pavakul K, Kulkantrakorn K, Choonhakarn C, Phonhiamhan S, Piyatrakul N, Aungaree T, Pongpakdee S, Yodnopaglaw P. (2010) Association between HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population. Epilepsia 51:926930.
  • Teerawattananon K, Iewsakul S, Yenjitr C, Ausayakhun S, Yenjitr W, Mugford M, Teerawattananon Y. (2007) Economic evaluation of treatment administration strategies of ganciclovir for cytomegalovirus retinitis in HIV/AIDS patients in Thailand: a simulation study. Pharmacoeconomics 25:413428.
  • Thai Association for the Study of Pain. (2008) Clinical practice guideline for neuropathic pain. Beyond Enterprises, Bangkok, Thailand.
  • Thavorncharoensap M, Lertpitakpong Y, Yothasamut J, Thitiboonsuwan K, Neramitpitagkul P, Teerawattananon Y. (2008) A study on cost of social, health and economic consequences of alcohol consumption in Thailand. Health Intervention and Technology Assessment Program, Nonthaburi, Thailand.
  • The Epilepsy Society of Thailand, Prasat Neurological Institute. (2011) Clinical practice guidelines for epilepsy. The Epilepsy Society of Thailand, Prasat Neurological Institute, Bangkok, Thailand.
  • The EuroQol Group. (1990) EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 16:199208.
  • The Health Economic Working Group. (2012) Meeting of the Health Economic Working Group on 30 March 30 2012. Food and Drug Administration, Ministry of Public Health, Nonthaburi, Thailand.
  • The Thai Working Group on Burden of Disease and Injuries. (2004) Burden of disease and injuries in Thailand: priority setting for policy. International Health Policy Program, Ministry of Public Health, Nonthaburi, Thailand.
  • The WHO Collaborating Centre for Drug Statistics Methodology. (2012) The defined daily dose. The WHO Collaborating Centre for Drug Statistics Methodology, Oslo, Norway.
  • The World Economic Outlook Database. (2012) The international monetary fund. The World Economic Outlook Database, Washington DC, USA.
  • Tongsiri S. (2009) The Thai population-based preference scores. London School of Hygiene and Tropical Medicine, University of London, London, UK.
  • Walters SJ, Campbell MJ. (2005) The use of bootstrap methods for estimating sample size and analysing health-related quality of life outcomes. Stat Med 24:10751102.